- Home
- GIFT vs APLT Comparison
GIFT vs APLT Comparison
Compare GIFT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIFT
- APLT
- Stock Information
- Founded
- GIFT 1999
- APLT 2016
- Country
- GIFT United States
- APLT United States
- Employees
- GIFT N/A
- APLT N/A
- Industry
- GIFT Catalog/Specialty Distribution
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- GIFT Consumer Discretionary
- APLT Health Care
- Exchange
- GIFT Nasdaq
- APLT Nasdaq
- Market Cap
- GIFT 40.4M
- APLT 44.0M
- IPO Year
- GIFT N/A
- APLT 2019
- Fundamental
- Price
- GIFT $1.14
- APLT $0.42
- Analyst Decision
- GIFT Strong Buy
- APLT Buy
- Analyst Count
- GIFT 1
- APLT 7
- Target Price
- GIFT $4.00
- APLT $6.10
- AVG Volume (30 Days)
- GIFT 61.6K
- APLT 2.7M
- Earning Date
- GIFT 08-15-2025
- APLT 08-06-2025
- Dividend Yield
- GIFT N/A
- APLT N/A
- EPS Growth
- GIFT N/A
- APLT N/A
- EPS
- GIFT N/A
- APLT N/A
- Revenue
- GIFT $89,689,155.00
- APLT $265,000.00
- Revenue This Year
- GIFT $12.22
- APLT $1,768.13
- Revenue Next Year
- GIFT $13.86
- APLT $292.85
- P/E Ratio
- GIFT N/A
- APLT N/A
- Revenue Growth
- GIFT 6.13
- APLT N/A
- 52 Week Low
- GIFT $0.50
- APLT $0.30
- 52 Week High
- GIFT $4.22
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- GIFT N/A
- APLT 60.22
- Support Level
- GIFT N/A
- APLT $0.32
- Resistance Level
- GIFT N/A
- APLT $0.36
- Average True Range (ATR)
- GIFT 0.00
- APLT 0.04
- MACD
- GIFT 0.00
- APLT 0.01
- Stochastic Oscillator
- GIFT 0.00
- APLT 88.67
About GIFT RDE Inc. Common Stock
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.